Special Issue

Antibiotic-Associated Dysbiosis and Management

Message from the Guest Editor

Antibiotic-associated dysbiosis refers to the imbalance of the mucosal microbiota caused by antibiotic treatments, which can lead to various adverse health outcomes. The aim of this Special Issue is to explore the complex interactions between antibiotics, dysbiosis, and immunity, as well as the application of innovative interventions to manage dysbiosis and restore the health of the microbiota. Topics of interest include, but are not limited to, the following:

- Dysbiosis: Investigations into the disruption of the microbial balance in the gut and other mucosal surfaces due to antibiotic use.
- Mucosal or systemic Immunity: Research exploring how dysbiosis affects mucosal immune responses and the overall immune system.
- Microbiota: Insights into the composition and function of microbiota communities in health and disease, particularly in the context of antibiotic exposure.
- Management or Intervention: Innovative strategies and interventions aimed at preventing or managing antibiotic-associated dysbiosis and restoring microbial balance.

Guest Editor

Prof. Dr. Yuseok Moon

Laboratory of Mucosal Exposome and Biomodulation, Department of Integrative Biomedical Sciences, Biomedical Research Institute, Pusan National University, Yangsan 50612, Republic of Korea

Deadline for manuscript submissions

closed (20 September 2025)



an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/210510

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

